Page last updated: 2024-08-26

sr141716 and Liver Dysfunction

sr141716 has been researched along with Liver Dysfunction in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chorvat, RJ	1
Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Dawson, AJ; Elshewehy, AMM; Kilpatrick, ES; Sathyapalan, T	1
Avraham, Y; Berry, EM; Gabbay, E; Ilan, Y; Israeli, E	1
Deveaux, V; Hezode, C; Lotersztajn, S; Mallat, A; Teixeira-Clerc, F; Tran van Nhieu, J	1

Reviews

2 review(s) available for sr141716 and Liver Dysfunction

Article	Year
Peripherally restricted CB1 receptor blockers. Bioorganic & medicinal chemistry letters, 2013, Sep-01, Volume: 23, Issue:17 Topics: Animals; Brain; Cocaine; Drug Discovery; Humans; Liver Diseases; Metabolic Diseases; Morpholines; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sulfonamides	2013
Endocannabinoids and liver disease--review. Liver international : official journal of the International Association for the Study of the Liver, 2005, Volume: 25, Issue:5 Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Endocannabinoids; Glycerides; Humans; Liver Diseases; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2005

Trials

1 trial(s) available for sr141716 and Liver Dysfunction

Article	Year
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC endocrine disorders, 2017, Jul-14, Volume: 17, Issue:1 Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Liver Diseases; Metformin; Obesity; Orlistat; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prognosis; Pyrazoles; Receptor, Cannabinoid, CB1; Retrospective Studies; Rimonabant; Thiazolidinediones; Weight Loss	2017

Article

Year

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.

BMC endocrine disorders, 2017, Jul-14, Volume: 17, Issue:1

Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Liver Diseases; Metformin; Obesity; Orlistat; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prognosis; Pyrazoles; Receptor, Cannabinoid, CB1; Retrospective Studies; Rimonabant; Thiazolidinediones; Weight Loss

2017

Other Studies

1 other study(ies) available for sr141716 and Liver Dysfunction

Article	Year
[Endocannabinoids: therapeutic perspectives in chronic liver diseases]. Gastroenterologie clinique et biologique, 2007, Volume: 31, Issue:3 Topics: Animals; Appetite Depressants; Cannabinoid Receptor Modulators; Cannabinoids; Chronic Disease; Disease Models, Animal; Disease Progression; Endocannabinoids; Fatty Liver; Glycolysis; Hepatitis C, Chronic; Hepatocytes; Humans; Hypertension, Portal; Lipogenesis; Liver; Liver Cirrhosis; Liver Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant	2007

Article

Year

[Endocannabinoids: therapeutic perspectives in chronic liver diseases].

Gastroenterologie clinique et biologique, 2007, Volume: 31, Issue:3

Topics: Animals; Appetite Depressants; Cannabinoid Receptor Modulators; Cannabinoids; Chronic Disease; Disease Models, Animal; Disease Progression; Endocannabinoids; Fatty Liver; Glycolysis; Hepatitis C, Chronic; Hepatocytes; Humans; Hypertension, Portal; Lipogenesis; Liver; Liver Cirrhosis; Liver Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant

2007